Free Newsletter
UCB's Cimzia touted as potential top-seller
Belgium's UCB is riding high today after it won the FDA nod for a new indication for Cimzia as a rheumatoid arthritis remedy. Company officials and some analysts said the drug could be an up-and-coming blockbuster. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: